Pfizer Inc. expects some pharmaceutical brands will be impacted by stay-at-home orders and fewer physician visits in the second quarter as a result of the global COVID-19 pandemic, but reaffirmed 2020 sales and earnings guidance while reporting first quarter financial results on 28 April.
CEO Albert Bourla said during a same-day conference call that the guidance reflects the strength and resiliency of the business...








